STAAR (STAA) Q2 2026 Earnings Call Transcript

STAAR Surgical reported Q2 net sales of $93.5M (+111% YoY), driven by China ($52.3M, +100%+ YoY) and the Americas (+12% YoY), while returning to profitability with net income of $8.1M (EPS $0.16) and adjusted EBITDA of $20.0M (vs. -$14.8M a year earlier). Gross margin rose 50 bps to 74.5% helped by lower Switzerland ramp-up and operating expenses of $59.6M (down 5% YoY), though margins were pressured by China tariffs on U.S.-manufactured product. Cash increased to $181.5M (from $163.9M at Q1) with expectations for free cash flow in H2 and year-end cash well above $200M, alongside progress on ERP and preparations for first-in-human studies of a next-generation product.

Analysis

This is less a one-quarter story than a proof that the mix shift in refractive surgery is real and still early. STAA is winning on procedure economics and surgeon workflow, which means the share gain can persist even if underlying market growth stays only mid-single digits; that is the part the market tends to miss. The second-order winner is the surgeon/practice that can monetize premium lens-based cases, while the real losers are laser-dependent refractive workflows and any public eye-care name exposed to substitution without product differentiation.

Near term, the setup is messier than the headline implies. Q3 will look seasonally softer and the comp is cleaner, so the stock can easily be sold on deceleration optics even if demand remains intact; the real falsifier is not year-over-year growth, but whether revenue can hold above the adjusted clean base while gross margin stays roughly in the mid-70s despite tariff drag. The biggest operational swing factor over the next 6-18 months is the Swiss manufacturing transition: if it slips, tariff leakage caps earnings power and delays multiple expansion even if top-line momentum continues.

Contrarian view: the market may be underestimating how sticky China share gains become once supply catches up. Consensus seems to be treating the premium SKU mix as a temporary uplift, but if EVO Plus becomes the default entry point and the company clears backorders, the revenue bridge into 2027 can step up faster than modeled. The upside is real, but it is not frictionless; margin expansion likely lags sales because tariffs, freight, and supply-chain normalization will keep the P&L from reflecting the full demand strength immediately.

Key Decisions for Investors

• STAA: Start a starter long only on weakness after the next print; best entry is a 5-10% pullback or any post-earnings selloff driven by Q3 seasonality, with a 12-18 month thesis tied to China share gains and the Swiss manufacturing margin reset.
• STAA: For convex upside, use a Jan-2027 call spread struck roughly 10-15% out of the money rather than common stock; the key catalyst path is 1H27 next-generation data plus tariff relief from full Swiss conversion.
• STAA: Trim or avoid adding if Q3 revenue fails to clear the adjusted clean base or if gross margin does not hold near the mid-70s; that would signal the market is right to focus on tariff and supply constraints.
• No clean pair trade today: do not force a short in broader ophthalmology names like ALC or BLCO unless follow-up checks show the share gains are broadening into industry-wide refractive weakness rather than just STAA-specific execution.